OSCCHNSCCVUmcfirst line therapy
…and memory B cells, plasmablasts and plasma cells in TIL-B high OSCC. In tumors enriched for plasmablasts, heterogeneous expression …
Browse by entity family
An entity family is a category of extracted information. Choose one to browse its named entities and supporting articles.
Funders
Organisations named as supporting, sponsoring, or funding research.
5,089 articles · 9,137 mentionsInstitutionsUniversities, hospitals, research centres, networks, and public bodies.
11,350 articles · 22,378 mentionsDrugsNamed medicines, compounds, vaccines, and pharmacological agents.
10,506 articles · 58,393 mentionsDiseasesNamed diseases, disorders, syndromes, injuries, and health conditions.
23,712 articles · 125,551 mentionsTreatmentsClinical therapies and care approaches used to manage a condition.
7,227 articles · 16,644 mentionsInterventionsProgrammes, procedures, policies, and other actions being evaluated.
4,132 articles · 9,994 mentionsClinical instrumentsNamed questionnaires, scales, scores, indices, and other clinical outcome assessments.
945 articles · 1,957 mentions29,499matching articles
244,054matching entity mentions
30popular entities listed
0%of mentions human-reviewed
Popular entities in these results
Choose an entity to see the articles in which it was identified.
EMBASE784PUBMED717COVID-19645Cancer605SLE570Diabetes552NHS522WEB OF SCIENCE499Hypertension418SCOPUS417HIV406Systemic Lupus Erythematosus390Heart Failure364Asthma349Stroke336COPD331WHO330Colorectal Cancer327Cardiovascular Disease317Type 2 Diabetes316Chronic Obstructive Pulmonary Disease313Joanna Briggs Institute306MEDLINE306Atrial Fibrillation283Cochrane Library275Breast Cancer271Hepatocellular Carcinoma253SSc251Inflammatory Bowel Disease250Obesity246
Matching articles
29,499 articles · page 396 of 2459HNSCCcuSCCPembrolizumabNational Institutes of HealthIRDye®700DXASP-1929NIHASP-1929 PIT
…ndard of care (SOC) surgical resection.Methods Nine patients (7 HNSCC, 2 cuSCC) received ASP-1929 PIT, followed by SOC surgical resec…
Rhabdomyosarcomacyclophosphamidesolid tumorsRMSChimeric antigen receptor (CAR) T therapyCART therapy
…i A, Ahmadi M, Logue S, Orive G, Pecic S, Gordon JW, Ghavami S. Rhabdomyosarcoma: current therapy, challenges, and future approaches to treatmen…
breast cancersolid tumorsBWH Innovation FundThe Harvard Ludwig CenterBCcellular therapiesCAR-MoPMA
…AMs) promote angiogenesis, metastasis, and immunosuppression in breast cancer (BC), contributing to resistance to immune checkpoint blockade …
blood cancerssolid tumorsNeo4Chimeric antigen receptor (CAR) T cell therapyNeo4-conjugatedScripps Research InstituteScripps Animal Care and Use ProgramACTadoptive T cell therapy
…ceptor (CAR) T cell therapy has revolutionized the treatment of blood cancers, but its efficacy against solid tumors remains limited. Cytokin…
AZD0240colorectal cancerpancreatic cancerPDACCRChuman cancerTCR-T cell therapy
…reatment of solid cancers, including PDAC and CRC, we developed AZD0240, a CRISPR-engineered autologous TCR-T cell product targeting KR…
PDS0101bintrafusp alfaadvanced HPV-associated malignanciesNHS-IL12BAPDS01ADCHPV16+ diseaseNCT04287868triple negative breast cancer
…redict patients who derive clinical benefit from treatment with PDS0101, NHS-IL12, and BA, based on baseline levels and early changes i…
Risankizumabulcerative colitisTulisokibartInflammatory bowel diseasesurgical interventionTNBS-induced colitisIBD
…human TL1A antibody Tulisokibart, anti-human IL-23 p19 antibody Risankizumab, alone or in combination, reduced the weight loss, DAI scores a…
Sanford Burnham PrebysPSGL-1melanoma tumorsThe NIH Shared Instrumentation Grant S10OD032325PSGL1
…32325 for the Cytek Aurora housed in the Flow Cytometry Core at Sanford Burnham Prebys.References 1.Hope JL, Otero DC, Bae EA, Stairiker CJ, Palete AB…
HCB301M7824atezolizumabnon-Hodgkin’s lymphomarituximabFDA
…F-β individually, in both FaDu and 4T1 tumor models.Conclusions HCB301 represents a novel therapeutic approach that simultaneously tar…
pembrolizumabCRCColorectal cancer
…den, survival, DNA-damage, immune infiltration, and response to pembrolizumab was assessed.Results A prefoldin protein, previously reported a…
AtezolizumabBevacizumabAtezo/BevHCCFudan Universityhepatocellular carcinomaImmune-checkpoint blockade therapiesZhongshan Hospital
… hepatocellular carcinoma (HCC) exhibiting varying responses to Atezolizumab plus Bevacizumab (Atezo/Bev), and profiled the tumor ecosystems…